BAXTER INTERNATIONAL INC (BAX) Financial Ratio Screen

NYSE Healthcare United States USD 13700M
RATIOS FAIL*
Automated financial screen · activity assessed separately
BAXTER INTERNATIONAL INC (BAX) is potentially non-compliant in the automated ratio model. The company's debt ratio of 48.8% exceeds the 30% MSCI new-inclusion threshold relative to total assets. BAXTER INTERNATIONAL INC operates in the Healthcare sector.

Track BAX screening changes

Get an email when this stock's published screening status or underlying ratios change.

MSCI new-inclusion financial-ratio snapshot

BAX financial screening at a glance

RATIOS FAIL*Financial ratios shown separately from business review — not a fatwa
Debt ratio
48.8%
Fail vs 30%
Cash ratio
9.8%
Pass vs 30%
Receivables + cash
19.4%
Pass vs 30%
Impermissible income
0.5%
Pass vs 5%

Calculation date: 2026-08-31. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleFinancial criteria not metAt least one available ratio exceeds its threshold
FTSE/Yasaar-styleFinancial criteria not metAt least one available ratio exceeds its threshold
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodDecember 2025Calculation date2026-08-31S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Medical Instruments & Supplies) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI 48.8%
/ 30%
9.8%
/ 30%
19.4%
/ 30%
0.46%
/ 5%
RATIOS FAIL*
FTSE 48.8%
/ 33%
9.8%
/ 33%
19.4%
/ 50%
0.46%
/ 5%
RATIOS FAIL*

Financial Highlights

EPS
$-1.88
Dividend Yield
15.0%
Payout: 307.7%
P/B Ratio
2.2
EV/EBITDA
11.2
EV: $21.2B
Revenue
$11.2B
Growth: 5.3%
Beta
0.6
Low volatility
Current Ratio
1.9

Profitability

Gross Margin 34.1%
Operating Margin 14.4%
Net Margin -9.3%
Return on Equity (ROE) -14.4%
Return on Assets (ROA) 2.8%

Cash Flow & Balance Sheet

Operating Cash Flow$845M
Free Cash Flow$323M
Total Debt$9.8B
Debt-to-Equity156.4
Current Ratio1.9
Total Assets$20.1B

Price & Trading

Last Close$26.29
50-Day MA$23.95
200-Day MA$20.08
Avg Volume6.8M
Beta0.6
52-Week Range
$15.73
$30.00

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-08-27 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About BAXTER INTERNATIONAL INC (BAX)

CEO
Mr. Andrew P. Hider
Employees
37,500
Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Exchange
NYSE
Market Cap (listing currency)
USD 13700M
Currency
USD

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is BAXTER INTERNATIONAL INC (BAX) halal to invest in?

The current automated result is Financial criteria not met or an activity exclusion was detected. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is BAXTER INTERNATIONAL INC's debt ratio?

BAXTER INTERNATIONAL INC's debt ratio is 48.8% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are BAXTER INTERNATIONAL INC's key financial metrics?

BAXTER INTERNATIONAL INC has a market capitalization of USD 13700M in its listing currency, and revenue of $11.2B. The company maintains a gross margin of 34.1% and a net margin of -9.3%. Return on equity stands at -14.4%.

How often is the screening data updated?

Calculation date: 2026-08-31. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.